FDA's Orphan Drugs Program

Development of drugs for rare diseases

Incentives for Rare Disease Drug Development

The FDA’s Orphan Drug Program was established to encourage the development of drugs for rare diseases that affect fewer than 200,000 people in the U.S.

Because these diseases often lack market incentives due to small patient populations, the FDA offers benefits and protections to make developing these therapies more feasible for pharmaceutical companies.

By offering incentives such as market exclusivity for seven years, tax credits for clinical trials, and waived user fees, the program helps mitigate the financial risks for companies developing treatments for these conditions. Additionally, the program provides guidance and grants to support research and development efforts.

Since its inception in 1983, the program has led to the approval of over 1,100 orphan drugs, significantly improving treatment options for patients with rare diseases and conditions that previously lacked effective therapies.

Key Program Goals

  • Stimulate research and development of drugs for rare diseases
  • Ensure patients with rare conditions have access to safe and effective treatments
  • Reduce the economic and regulatory barriers that discourage investment

What Qualifies a Drug for Orphan Status?

To qualify:

  1. The drug must treat, diagnose, or prevent a disease or condition affecting fewer than 200,000 people in the U.S., or
  2. If the population is larger, the sponsor must show there is no reasonable expectation of recovering development costs through U.S. sales.

Benefits of Orphan Drug Designation

When a product is granted orphan drug status, the sponsor receives several incentives:

Benefit Description
7 Years of Market Exclusivity After approval, the FDA will not approve a similar drug for the same indication
Tax Credits Up to 25% of qualified clinical trial costs
Waived User Fees FDA application and annual product fees may be waived
Assistance from FDA Access to the Orphan Products Grants Program and guidance on study design
Eligibility for Grants Competitive grant funding for clinical trials through the Office of Orphan Products Development (OOPD)

Process Overview

  1. Sponsor applies for Orphan Drug Designation before submitting an NDA/BLA
  2. FDA reviews the application and grants designation if criteria are met
  3. After successful clinical trials, sponsor submits a marketing application
  4. If approved, the 7-year exclusivity and other incentives apply

Impact of the Program

  • Over 1,100 orphan drugs have been approved since 1983
  • Conditions treated range from rare cancers to genetic disorders, autoimmune diseases, and metabolic syndromes
  • Has dramatically increased investment in previously neglected diseases

Examples of Orphan Drug Approvals

  • Spinraza (nusinersen) – for spinal muscular atrophy
  • Luxturna (voretigene neparvovec) – for inherited retinal dystrophy
  • Zolgensma (onasemnogene abeparvovec) – gene therapy for SMA
  • Lynparza (olaparib) – for BRCA-mutated ovarian cancer
  • Lynozyfic (linvoseltamab-gcpt) – for relapsed/refractory multiple myeloma (recent)

 Summary

Feature Orphan Drug Program
Target Diseases Rare (≤200,000 U.S. patients)
Lead FDA Office Office of Orphan Products Development (OOPD)
Key Benefits Market exclusivity, tax credits, fee waivers
Approval Path NDA/BLA after orphan designation
Major Goal

Encourage R&D for underserved patient populations

Read more about the program.

Read about the Orphan Drugs Program on the FDA website. 

Recently approved novel drugs

News

FDA Enforcement

Safety Alerts

Medical Devices

Pharma

New Drugs

Drug Shortages

Pimicotinib (Pimjetmi) for Tenosynovial Giant Cell Tumor

On November 10, 2026, the Food and Drug Administration approved pimicotinib (Pimjetmi, EMD Serono, Inc.), a kinase inhibitor, for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or...

Eugia Vancomycin Recall: Glass Particle Contamination

FDA announces voluntary recall of a single lot of vancomycin hydrochloride for injection because of potentially dangerous particulate contamination.Eugia US LLC, formerly Auro Medics Pharma LLC, has initiated a voluntary nationwide recall of one lot of Vancomycin...

FDA Requires New GLP-1 Drug Warning for Vision Loss Risk

Agency cites potential increased risk of rare optic nerve condition following review of clinical trials and postmarket safety dataThe U.S. Food and Drug Administration (FDA) is requiring manufacturers of all glucagon-like peptide-1 receptor agonist (GLP-1 RA)...